News for Tandem Diabetes Care, Inc. (TNDM)

Shares of Tandem Diabetes Care Inc (TNDM) fell 3.56% in mid-day trading on Jul 15. The stock reached an intraday low of $14.92, before recovering slightly to

PR NewswireNEW YORK, July 15, 2025 MarketNewsUpdates News CommentaryNEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are rev

Leerink has revised its price target for Tandem Diabetes (TNDM), reducing it from $48 to $38. Despite the adjustment, the firm maintains an Outperform rating on

Shares of Tandem Diabetes Care Inc (TNDM) fell 3.49% in mid-day trading on Jul 11. The stock reached an intraday low of $15.44, before recovering slightly to

Shares of Tandem Diabetes Care Inc (TNDM) fell 5.72% in mid-day trading on Jul 9. The stock reached an intraday low of $15.17, before recovering slightly to $

Tandem Diabetes (TNDM) received a downgrade from Citi, with analyst Joanne Wuensch shifting her rating from Neutral to Sell. The new price target for TNDM is se

Tandem Diabetes Care's t:slim X2 insulin pump now integrates seamlessly with Abbott's FreeStyle Libre 3 Plus glucose monitor. Analysts forecast signific

Summary Tandem Diabetes Care Inc (TNDM), a leader in insulin delivery and diabetes technology, has announced the integration of its Tandem t:slim X2â„¢ insulin

PALM BEACH, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global diabetic retinopathy market has shown a consistent growth in r

Abbott Laboratories (NYSE:ABT) is one of the best stocks to buy for beginners now. On June 10, Tandem Diabetes Care Inc. (NASDAQ:TNDM) announced a new agreement with Abbott to develop and commercialize integrated diabetes solutions. The collaboration will combine Abbott’s future dual glucose-ketone sensor with Tandem’s innovative insulin delivery systems, with the aim of providing […]

On June 16, 2025, Tandem Diabetes Care (TNDM) garnered attention as Truist Securities initiated coverage on the company. Renowned analyst Richard Newitter spear

Truist has begun coverage of Tandem Diabetes (TNDM) with a Hold rating and set a price target of $24. The company's new product launches are expected to bolster

Abbott Laboratories partners with Tandem Diabetes for advanced diabetes management solutions. Wall Street analysts see significant upside potential for

[url="]Tandem Diabetes Care, Inc.[/url] (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and

Tandem Diabetes Care shows improving revenue and margins, but faces ongoing losses, high expenses, and stiff competition from larger players. Learn more on TNDM stock here.

Shares of Tandem Diabetes Care Inc (TNDM) fell 3.10% in mid-day trading on May 30. The stock reached an intraday low of $20.51, before recovering slightly to

Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has agreed to pay Roche $36 million to resolve a patent infringement lawsuit over Tandem’s t:slim X2 insulin pump. The deal settles all pending and prospective litigation about two European patents that Roche filed in December 2023, EP 2 196 231 B1 and EP 1 970 677 B1. Over the […]

Key Highlights: Tandem Diabetes Care resolves patent disputes with Roche for $36 million over five years. Wall Street analysts suggest a 63.08% upside po